Although the PI3K-AKT pathway presents a relatively low overall mutation rate in ccRCC when compared to other cancer types, the overall activation of AKT and downstream substrates is high [24–26]. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.